title: First-line therapy for advanced colorectal cancer.
abstract: First-line therapy for advanced colorectal cancer is rapidly moving from modulation and infusional administration of fluoropyrimidines in the past decades to more complex and more active regimens, with new chemotherapy drugs, oxaliplatin and irinotecan, and modulated targeted drugs inhibiting angiogenesis or the epidermal growth factor receptor (EGFR). The choice of first-line therapy is becoming more complex and is part of a global strategy also integrating individual prognostic factors, salvage surgery, and second-line therapy. Furthermore, we fear that limited financial resources will also influence the management of this disease.
authors.affiliation: Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris, Cedex 12, France. aimery.de-gramont@sat.aphp.fr
authors.forename: Aimery
authors.initials: A
authors.lastname: de Gramont
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
authors.forename: Christophe
authors.initials: C
authors.lastname: Louvet
authors.forename: Frédérique
authors.initials: F
authors.lastname: Maindrault-Goebel
authors.forename: Thierry
authors.initials: T
authors.lastname: André
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents